Mycobacterium marinum infection in Drosophila melanogaster for antimycobacterial activity assessment

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 601-609

  Oh, Chun Taek ^a   Moon, Cheol ^b   Choi, Tae Hyun ^c   Kim, Byoung Soo ^c   Jang, Jichan ^a  

^a Institute Pasteur Korea   (South Korea)

^b Semyung University   (South Korea)

^c Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Antimycobacterial drug; Drug discovery; Invertebrate model

Indexed keywords

AMIKACIN; AMPICILLIN; DIMETHYL SULFOXIDE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TRETAZICAR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; COLONY FORMING UNIT; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DROSOPHILA MELANOGASTER; DRUG EFFICACY; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; LIFESPAN; MYCOBACTERIOSIS; MYCOBACTERIUM MARINUM; NONHUMAN; SURVIVAL RATE;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; DROSOPHILA MELANOGASTER; DRUG EVALUATION, PRECLINICAL; MALE; MODELS, ANIMAL; MYCOBACTERIUM MARINUM; SURVIVAL ANALYSIS;

EID: 84873577806     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks425     Document Type: Article

References (41)

1. Dietrich J, Doherty TM. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS 2009; 117: 440-57.
2. Prasad R. Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions. Indian J Tuberc 2010; 57: 180-91.
3. Chamilos G, Samonis G, Kontoyiannis DP. Drosophila melanogaster as a model host for the study of microbial pathogenicity and the discovery of novel antimicrobial compounds. Curr Pharm Des 2011; 17: 1246-53.
4. Trede NS, Langenau DM, Traver D et al. The use of zebrafish to understand immunity. Immunity 2004; 20: 367-79.
5. Dodds PN, Rathjen JP. Plant immunity: towards an integrated view of plant-pathogen interactions. Nat Rev Genet 2010; 11: 539-48.
6. Ferrandon D, Imler JL, Hetru C et al. The Drosophila systemic immune response: sensing and signalling during bacterial and fungal infections. Nat Rev Immunol 2007; 7: 862-74.
7. Millet AC, Ewbank JJ. Immunity in Caenorhabditis elegans. Curr Opin Immunol 2004; 16: 4-9.
8. Dionne MS, Ghori N, Schneider DS. Drosophila melanogaster is a genetically tractable model host for Mycobacterium marinum. Infect Immun 2003; 71: 3540-50.
9. D'Argenio DA, Gallagher LA, Berg CA et al. Drosophila as a model host for Pseudomonas aeruginosa infection. J Bacteriol 2000; 183: 1466-71.
10. Fauvarque MO, Bergeret E, Chabert J et al. Role and activation of type III secretion system genes in Pseudomonas aeruginosa induced Drosophila killing. Microb Pathog 2002; 32: 287-95.
11. Needham AJ, Kibart M, Crossley H et al. Drosophila melanogaster as a model host for Staphylococcus aureus infection. Microbiology 2004; 150: 2347-55.
12. Mansfield BE, Dionne MS, Schneider DS et al. Exploration of host-pathogen interactions using Listeria monocytogenes and Drosophila melanogaster. Cell Microbiol 2003; 5: 901-11.
13. Tønjum T, Welty DB, Jantzen E et al. Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis. J Clin Microbiol 1998; 36: 918-25.
14. Cosma CL, Swaim LE, Volkman H et al. Zebrafish and frog models of Mycobacterium marinum infection. Curr Protoc Microbiol 2006; Chapter 10: Unit 10B 12.
15. Collins L, Franzblau SG. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997; 41: 1004-9.
16. Broughton SJ, Piper MD, Ikeya T et al. Longer lifespan, altered metabolism, and stress resistance in Drosophila from ablation of cells making insulin-like ligands. Proc Natl Acad Sci USA 2005; 102: 3105-10.
17. Dionne MS, Pham LN, Shirasu-Hiza M et al. Akt and FOXO dysregulation contribute to infection-induced wasting in Drosophila. Curr Biol 2006; 16: 1977-85.
18. Belanger AE, Besra GS, Ford ME et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996; 93: 11919-24.
19. Banerjee A, Dubnau E, Quemard A et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-30.
20. Zimhony O, Cox JS, Welch JT et al. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000; 6: 1043-7.
21. Lu P, Haagsma AC, Pham H et al. Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels. Antimicrob Agents Chemother 2011; 55: 5354-7.
22. Zhang Y, Wade MM, Scorpio A et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003; 52: 790-5.
23. Shi WL, Zhang XL, Jiang X et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011; 333: 1630-2.
24. Majtán V, L'Drobnica, Miko M. The effect of rifampicin on Mycobacterium smegmatis. Folia Microbiol (Praha) 1982; 27: 81-6.
25. Krüüner A, Jureen P, Levina K et al. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 2971-73.
26. Manina G, Pasca MR, Buroni S et al. Decaprenylphosphoryl-β-D-ribose 2′-epimerase from Mycobacterium tuberculosis is a magic drug target. Curr Med Chem 2010; 17: 3099-108.
27. Brady RC, Sheth A, Mayer T et al. Facial sporotrichoid infection with Mycobacterium marinum. J Pediatr 1997; 130: 324-6.
28. Aubry A, Jarlier V, Escolano S et al. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother 2000; 44: 3133-6.
29. Duclos S, Diez R, Garin J et al. Rab5 regulates the kiss and run fusion between phagosomes and endosomes and the acquisition of phagosome leishmanicidal properties in RAW 264.7 macrophages. J Cell Sci 2000; 113: 3531-41.
30. Tarshis MS, Weed WA Jr. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 1953; 67: 391-5.
31. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 1954; 70: 748-54.
32. Ivory A, Rändle K, Wu L. Cellular immune responses in Drosophila melanogaster. In: Heine H, ed. Innate Immunity of Plants, Animals, and Humans. Berlin: Springer-Verlag, 2008: 73-91.
33. Massie HR, Williams TR, Colacicco JR. Changes in pH with age in Drosophila and the influence of buffers on longevity. Mech Ageing Dev 1981; 16: 221-31.
34. Dickinson JM, Mitchison DA. Bactericidal activity in vitro and in the guinea pig of isoniazid, rifampicin and ethambutol. Tubercle 1976; 57: 251-8.
35. Dickinson JM, Aber VR, Mitchison DA. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 1977; 116: 627-35.
36. Prabhakaran K, Harris EB, Randhawa B. Bactericidal action of ampicillin/ sulbactam against intracellular mycobacteria. Int J Antimicrob Agents 1999; 13: 133-5.
37. Lionakis MS, Lewis RE, May GS et al. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis 2005; 191: 1188-95.
38. Chamilos G, Lionakis MS, Lewis RE et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 2006; 193: 1014-22.
39. Andersen SK, Gjedsted J, Christiansen C et al. The roles of insulin and hyperglycemia in sepsis pathogenesis. J Leukoc Biol 2004; 75: 413-21.
40. Oluboyo PO, Erasmus RT. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle 1990; 71: 135-8.
41. Lalande V, Truffot-Pernot C, Paccaly-Moulin A et al. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993; 37: 407-13.